CONMED Shares Decline Following Strategic Withdrawal from Gastroenterology Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy MEDP?
Source: NASDAQ.COM
CONMED's Strategic Shift: CONMED announced its exit from gastroenterology product lines, including an early termination of its distribution agreement with Gore for the VIABIL biliary stent, to focus on core areas like minimally invasive and orthopedic soft tissue surgery.
Financial Impact: The company expects a revenue loss of $90–$95 million from the gastroenterology segment in 2025 and anticipates earnings per share dilution of 45–55 cents in 2026, but aims to improve its gross margin profile by about 80 basis points in the long run.
Market Reaction: Following the announcement, CONMED's shares fell over 9%, reflecting investor concerns, as the company has seen a 41.5% decline in stock value year-to-date compared to industry growth.
Future Outlook: The exit is expected to streamline CONMED’s operations, enhance profitability, and allow for better resource allocation towards higher-growth potential areas, ultimately aiming for a more resilient business model.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 424.000
Low
462.00
Averages
569.17
High
660.00
Current: 424.000
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the company's misleading statements about cancellation rates and book-to-bill ratios, which led to a significant 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: Following the financial results announcement on February 9, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting investor concerns over the company's financial health and negatively impacting market expectations for future performance.
- Management Changes: Amid the lawsuit, Medpace's President Jesse Geiger announced his resignation, raising further concerns about the company's governance and management stability, which could lead to a decline in investor confidence.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have significant repercussions on Medpace's financial standing, exacerbating stock price volatility.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Arrangement: Investors participating in the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected investors to join.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, highlighting significant investor concern over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that their projected book-to-bill ratio for Q4 2025 was overstated, severely undermining investor confidence in the company's performance.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, causing the stock price to plummet nearly 16%, reflecting market concerns about the company's future growth prospects.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the importance of investor participation in legal proceedings.
See More
Medpace Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Medpace Holdings, alleging violations of federal securities laws from April 22, 2025, to February 9, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite having contrary internal information, misleading investors about the company's financial health.
- Investor Participation Opportunity: Affected investors have until June 5, 2026, to request appointment as lead plaintiff, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors in securities fraud class actions, underscoring their expertise and commitment to restoring investor capital and corporate accountability.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Notice: The Schall Law Firm has alerted investors about a class action lawsuit against Medpace Holdings for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public disclosures.
- Legal Representation Information: Schall Law Firm specializes in securities class actions and offers free consultations to affected investors, urging them to contact the firm before class certification to ensure their rights are protected and avoid being absent class members.
- Market Reaction: The exposure of the lawsuit may undermine investor confidence in Medpace, potentially leading to further stock price volatility, reflecting serious deficiencies in the company's transparency and compliance practices.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the company's misleading statements about cancellation rates and book-to-bill ratios, which led to a significant 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: Following the financial results announcement on February 9, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting investor concerns over the company's financial health and negatively impacting market expectations for future performance.
- Management Changes: Amid the lawsuit, Medpace's President Jesse Geiger announced his resignation, raising further concerns about the company's governance and management stability, which could lead to a decline in investor confidence.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have significant repercussions on Medpace's financial standing, exacerbating stock price volatility.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Arrangement: Investors participating in the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected investors to join.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, highlighting significant investor concern over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that their projected book-to-bill ratio for Q4 2025 was overstated, severely undermining investor confidence in the company's performance.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, causing the stock price to plummet nearly 16%, reflecting market concerns about the company's future growth prospects.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the importance of investor participation in legal proceedings.
See More
Medpace Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Medpace Holdings, alleging violations of federal securities laws from April 22, 2025, to February 9, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite having contrary internal information, misleading investors about the company's financial health.
- Investor Participation Opportunity: Affected investors have until June 5, 2026, to request appointment as lead plaintiff, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors in securities fraud class actions, underscoring their expertise and commitment to restoring investor capital and corporate accountability.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Notice: The Schall Law Firm has alerted investors about a class action lawsuit against Medpace Holdings for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public disclosures.
- Legal Representation Information: Schall Law Firm specializes in securities class actions and offers free consultations to affected investors, urging them to contact the firm before class certification to ensure their rights are protected and avoid being absent class members.
- Market Reaction: The exposure of the lawsuit may undermine investor confidence in Medpace, potentially leading to further stock price volatility, reflecting serious deficiencies in the company's transparency and compliance practices.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
See More
